APRIL 2018 – Rhythm is a biopharmaceutical company focused on developing therapies for rare genetic disorders of obesity. Their lead product, setmelanotide (RM-493), is now in phase 3 trial for other obesity disorders whilst a phase 2 trial in PWS achieved only modest success in reducing hyperhphagia. However, Rhythm are assessing opportunities to further evaluate it in PWS, which may be in parallel or in conjunction with their new acquisition of RM-853 as there may be complementary effects.
Setmelanotide is an MC4R agonist targeting the MC4 receptors which reside in the hypothalamus and promote satiety. RM-853 is a ghrelin o-acyltransferase (GOAT) inhibitor which is designed to block GOAT, the key enzyme involved in the production of the active form of ghrelin, a hormone which stimulates appetite. Read More >